Cardiotoxicity of Anthracyclines

Daniela Cardinale, Fabiani Iacopo, Carlo Maria Cipolla, Daniela Cardinale, Fabiani Iacopo, Carlo Maria Cipolla

Abstract

Cardiotoxicity is a feared side effect that may limit the clinical use of anthracyclines. It may indeed affect the quality of life and survival of patients with cancer, regardless of oncological prognosis. This paper provides an overview of anthracycline-induced cardiotoxicity in terms of definition, classification, incidence, risk factors, possible mechanisms, diagnosis, and treatment. We also report effective strategies for preventing cardiotoxicity. In addition, we discuss limiting current approaches, the need for a new classification, and early cardiotoxicity detection and treatment. Probably, anthracycline-induced cardiotoxicity is a continuous phenomenon that starts from myocardial cell injury; it is followed by left ventricular ejection fraction (LVEF) and, if not diagnosed and cured early, progressively leads to symptomatic heart failure. Anthracycline-induced cardiotoxicity can be detected at a preclinical phase. The role of biomarkers, in particular troponins, in identifying subclinical cardiotoxicity and its therapy with angiotensin-converting enzyme inhibitors (mainly enalapril) to prevent LVEF reduction is a recognized and effective strategy. If cardiac dysfunction has already occurred, partial or complete LVEF recovery may still be obtained in case of early detection of cardiotoxicity and prompt heart failure treatment.

Keywords: ACE-inhibitors; anthracyclines; beta-blockers; cardiotoxicity; early detection; prevention; reversibility; troponin.

Copyright © 2020 Cardinale, Iacopo and Cipolla.

Figures

Figure 1
Figure 1
Graphical representation of several doxorubicin-targeted cell types, with potential side effects and cellular and molecular events evoked by the drug. From Cappetta et al. (11).
Figure 2
Figure 2
Possible strategies for cancer drug-induced cardiotoxicity detection, prevention, and treatment. AC, anthracyclines; ACEI, angiotensin-converting enzyme inhibitors; BB, beta-blockers; CV, cardiovascular; GLS, global longitudinal strain; HF, heart failure; LVD, left ventricular dysfunction; RAS, renin-angiotensin system. From Cardinale et al. (8).
Figure 3
Figure 3
LVEF in patients with cardiotoxicity and with partial (triangle) or full (square) recovery with heart failure therapy. Data are mean ± SD. CT, chemotherapy; HF, heart failure. From Cardinale et al. (15).
Figure 4
Figure 4
(A) Percentage of patients who recovered (Responders), according to the time elapsed from anthracycline administration and the start of heart failure therapy. (B) Relationship between maximal LVEF during the follow-up period and log time elapsed from chemotherapy and the start of treatment [time-to-heart failure (HF) treatment]. From Cardinale et al. (31).
Figure 5
Figure 5
(A) Percentage of patients developing cardiac dysfunction in the enalapril-treated group (ACEI Group) and controls. (B) Incidence of cardiac events in patients treated with ACEI Group and in Controls. Modified from Cardinale et al. (90).

References

    1. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. (2012) 52:1213–25. 10.1016/j.yjmcc.2012.03.006
    1. Henriksen PA. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. (2018) 104:971–77. 10.1136/heartjnl-2017-312103
    1. Yeh ET, Chang HM. Oncocardiology-past, present, and future: a review. JAMA Cardiol. (2016) 1:1066–72. 10.1001/jamacardio.2016.2132
    1. Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, et al. . Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin. (2016) 66:309–25. 10.3322/caac.21341
    1. Bloom MW, Hamo CE, Cardinale D, Ky B, Nohria A, Baer L, et al. . Cancer therapy-related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging. Circ Heart Fail. (2016) 9:e002661. 10.1161/CIRCHEARTFAILURE.115.002661
    1. Tan C, Tasaka H, Yu KP, Murphy ML, Karnofsky DA. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer. (1967) 20:333–53. 10.1002/1097-0142(1967)20:3333::;2-k
    1. Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, et al. . 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail. (2017) 19:9–42. 10.1002/ejhf.654
    1. Cardinale D, Biasillo G, Cipolla CM. Curing cancer, saving the heart: a challenge that cardioncology should not miss. Curr Cardiol Rep. (2016) 18:51 10.1007/s11886-016-0731-z
    1. Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, et al. . Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. (2012) 18:1639–42. 10.1038/nm.2919
    1. Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. (2014) 64:938–45. 10.1016/j.jacc.2014.06.1167
    1. Cappetta D, Rossi F, Piegari E, Quaini F, Berrino L, Urbanek K, et al. . Doxorubicin targets multiple players: a new view of an old problem. Pharmacol Res. (2018) 127:4–14. 10.1016/j.phrs.2017.03.016
    1. Giantris A, Abdurrahman L, Hinkle A, Asselin B, Lipshultz SE. Anthracycline-induced cardiotoxicity in children and young adults. Crit Rev Oncol Hematol. (1998) 27:53–68. 10.1016/S1040-8428(97)10007-5
    1. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol. (1998) 25(4 Suppl. 10):72–85.
    1. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. (1991) 266:1672–7. 10.1001/jama.266.12.1672
    1. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. . Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. (2015) 131:1981–8. 10.1161/CIRCULATIONAHA.114.013777
    1. Eschenhagen T, Force T, Ewer MS, de Keulenaer GW, Suter TM, Anker SD, et al. . Cardiovascular side effects of cancer therapies: a position statement from the heart failure association of the European society of cardiology. Eur J Heart Fail. (2011) 13:1–10. 10.1093/eurjhf/hfq213
    1. Cardinale D, Biasillo G, Salvatici M, Sandri MT, Cipolla CM. Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy. Expert Rev Mol Diagn. (2017) 17:245–56. 10.1080/14737159.2017.1283219
    1. Cardinale D, Cipolla CM. Chemotherapy-induced cardiotoxicity: importance of early detection. Expert Rev Cardiovasc Ther. (2016) 14:1297–9. 10.1080/14779072.2016.1239528
    1. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. . Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. (2014) 15:1063–93. 10.1093/ehjci/jeu192
    1. Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. . Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol. (2017) 35:893–911. 10.1200/JCO.2016.70.5400
    1. Levis BE, Binkley PF, Shapiro CL. Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms? Lancet Oncol. (2017) 18:e445–56. 10.1016/S1470-2045(17)30535-1
    1. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. . Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. (2000) 342:1077–84. 10.1056/NEJM200004133421502
    1. Saini J, Rich MW, Lyss AP. Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity. Report of three cases. Ann Intern Med. (1987) 106:814–6. 10.7326/0003-4819-106-6-814
    1. Jensen BV, Nielsen SL, Skovsgaard T. Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet. (1996) 347:297–9. 10.1016/S0140-6736(96)90469-9
    1. Fazio S, Palmieri EA, Ferravante B, Bone F, Biondi B, Sacca L. Doxorubicin-induced cardiomyopathy treated with carvedilol. Clin Cardiol. (1998) 21:777–9. 10.1002/clc.4960211017
    1. Noori A, Lindenfeld J, Wolfel E, Ferguson D, Bristow MR, Lowes BD. Beta-blockade in adriamycin-induced cardiomyopathy. J Card Fail. (2000) 6:115–9. 10.1054/jcaf.2000.7505
    1. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. (2002) 13:699–709. 10.1093/annonc/mdf132
    1. Mukai Y, Yoshida T, Nakaike R, Mukai N, Iwato K, Kyo T, et al. . Five cases of anthracycline-induced cardiomyopathy effectively treated with carvedilol. Intern Med. (2004) 43:1087–8. 10.2169/internalmedicine.43.1087
    1. Tallaj JA, Franco V, Rayburn BK, Pinderski L, Benza RL, Pamboukian S, et al. . Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant. (2005) 24:2196–201. 10.1016/j.healun.2004.12.108
    1. Tabet JY, Meurin P, Ben Driss A, Berthaux X, Weber H, Renaud N, et al. . Beta-blockade intolerance in anthracycline-induced cardiomyopathy. Int J Cardiol. (2006) 106:132–4. 10.1016/j.ijcard.2004.12.052
    1. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, de Giacomi G, et al. . Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. (2010) 55:213–20. 10.1016/j.jacc.2009.03.095
    1. O'Brien PJ. Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity. Toxicology. (2008) 245:206–18. 10.1016/j.tox.2007.12.006
    1. Lipshultz SE, Rifai N, Sallan SE, Lipsitz SR, Dalton V, Sacks DB, et al. . Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation. (1997) 96:2641–8. 10.1161/01.CIR.96.8.2641
    1. Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, et al. . Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. (2000) 36:517–22. 10.1016/S0735-1097(00)00748-8
    1. Cardinale D, Sandri MT, Martinoni A, Borghini E, Civelli M, Lamantia G, et al. . Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol. (2002) 13:710–5. 10.1093/annonc/mdf170
    1. Auner HW, Tinchon C, Linkesch W, Tiran A, Quehenberger F, Link H, et al. . Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol. (2003) 82:218–22. 10.1007/s00277-003-0615-3
    1. Sandri MT, Cardinale D, Zorzino L, Passerini R, Lentati P, Martinoni A, et al. . Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem. (2003) 49:248–52. 10.1373/49.2.248
    1. Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al. . Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. (2004) 109:2749–54. 10.1161/
    1. Specchia G, Buquicchio C, Pansini N, Di Serio F, Liso V, Pastore D, et al. . Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines. J Lab Clin Med. (2005) 145:212–20. 10.1016/j.lab.2005.02.003
    1. Kilickap S, Barista I, Akgul E, Aytemir K, Aksoyek S, Aksoy S, et al. . cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol. (2005) 16:798–804. 10.1093/annonc/mdi152
    1. Lee HS, Son CB, Shin SH, Kim YS. Clinical correlation between brain natriutetic peptide and anthracyclin-induced cardiac toxicity. Cancer Res Treat. (2008) 40:121–6. 10.4143/crt.2008.40.3.121
    1. Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, et al. . Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. (2008) 26:5204–12. 10.1200/JCO.2007.15.6331
    1. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al. . Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. (2010) 28:3910–6. 10.1200/JCO.2009.27.3615
    1. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V, et al. . Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. (2011) 107:1375–80. 10.1016/j.amjcard.2011.01.006
    1. Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, et al. . Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. (2010) 11:950–61. 10.1016/S1470-2045(10)70204-7
    1. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, et al. . Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. (2012) 5:596–603. 10.1161/CIRCIMAGING.112.973321
    1. Drafts BC, Twomley KM, D'Agostino R, Jr, Lawrence J, Avis N, et al. . Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging. (2013) 6:877–85. 10.1016/j.jcmg.2012.11.017
    1. Mornos C, Petrescu L. Early detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist. Can J Physiol Pharmacol. (2013) 91:601–7. 10.1139/cjpp-2012-0398
    1. Mavinkurve-Groothuis AM, Marcus KA, Pourier M, Loonen J, Feuth T, Hoogerbrugge PM, et al. . Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study. Eur Heart J Cardiovasc Imaging. (2013) 14:562–9. 10.1093/ehjci/jes217
    1. Ky B, Putt M, Sawaya H, French B, Januzzi JL, Jr, Sebag IA, et al. . Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. (2014) 63:809–16. 10.1016/j.jacc.2013.10.061
    1. Mornos C, Manolis AJ, Cozma D, Kouremenos N, Zacharopoulou I, Ionac A. The value of left ventricular global longitudinal strain assessed by three-dimensional strain imaging in the early detection of anthracyclinemediated cardiotoxicity. Hellenic J Cardiol. (2014) 55:235–44.
    1. Putt M, Hahn VS, Januzzi JL, Sawaya H, Sebag IA, Plana JC, et al. . Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab. Clin Chem. (2015) 61:1164–72. 10.1373/clinchem.2015.241232
    1. Zardavas D, Suter TM, van Veldhuisen DJ, Steinseifer J, Noe J, Lauer S, et al. . Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab: a herceptin adjuvant study cardiac marker substudy. J Clin Oncol. (2017) 35:878–84. 10.1200/JCO.2015.65.7916
    1. Olivieri J, Perna GP, Bocci C, Montevecchi C, Olivieri A, Leoni P, et al. . Modern management of anthracycline-induced cardiotoxicity in lymphoma patients: low occurrence of cardiotoxicity with comprehensive assessment and tailored substitution by nonpegylated liposomal doxorubicin. Oncologist. (2017) 22:422–31. 10.1634/theoncologist.2016-0289
    1. Kitayama H, Kondo T, Sugiyama J, Kurimoto K, Nishino Y, Kawada M, et al. . High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients. Breast Cancer. (2017) 24:774–82. 10.1007/s12282-017-0778-8
    1. Shafi A, Siddiqui N, Imtiaz S, Din Sajid MU. Left ventricular systolic dysfunction predicted by early troponin I release after anthracycline based chemotherapy in breast cancer patients. J Ayub Med Coll Abbottabad. (2017) 29:266–9.
    1. Lenihan DJ, Stevens PL, Massey M, Plana JC, Araujo DM, Fanale MA, et al. . The utility of point-of-care biomarkers to detect cardiotoxicity during anthracycline chemotherapy: a feasibility study. J Card Fail. (2016) 22:433–8. 10.1016/j.cardfail.2016.04.003
    1. Feola M, Garrone O, Occelli M, Francini A, Biggi A, Visconti G, et al. . Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol. (2011) 148:194–8. 10.1016/j.ijcard.2009.09.564
    1. Sandri MT, Salvatici M, Cardinale D, Zorzino L, Passerini R, Lentati P, et al. . N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem. (2005) 51:1405–10. 10.1373/clinchem.2005.050153
    1. Hoeger CW, Hayek SS. Role of cardiovascular biomarkers in the risk stratification, monitoring, and management of patients with cancer. Cardiol Clin. (2019) 37:505–23. 10.1016/j.ccl.2019.07.015
    1. Weir RA, Petrie CJ, Murphy CA, Clements S, Steedman T, Miller AM, et al. Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circ Heart Fail. (2013) 6:492–8. 10.1161/CIRCHEARTFAILURE.112.000146
    1. Freres P, Bouznad N, Servais L, Josse C, Wenric S, Poncin A, et al. . Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients. BMC Cancer. (2018) 18:102. 10.1186/s12885-018-4015-4
    1. Oliveira-Carvalho V, Ferreira LR, Bocchi EA. Circulating mir-208a fails as a biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients. J Appl Toxicol. (2015) 35:1071–2. 10.1002/jat.3185
    1. Armenian SH, Gelehrter SK, Vase T, Venkatramani R, Landier W, Wilson KD, et al. . Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors. Clin Cancer Res. (2014) 20:6314–23. 10.1158/1078-0432.CCR-13-3490
    1. van Boxtel W, Bulten BF, Mavinkurve-Groothuis AM, Bellersen L, Mandigers CM, Joosten LAF, et al. . New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide. Biomarkers. (2015) 20:143–8. 10.3109/1354750X.2015.1040839
    1. Narayan HK, Finkelman B, French B, Plappert T, Hyman D, Smith AM, et al. . Detailed echocardiographic phenotyping in breast cancer patients: associations with ejection fraction decline, recovery, and heart failure symptoms over 3 years of follow-up. Circulation. (2017) 135:1397–12. 10.1161/CIRCULATIONAHA.116.023463
    1. Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. (2014) 63(25 Pt A):2751–68. 10.1016/j.jacc.2014.01.073
    1. Brown J, Jenkins C, Marwick TH. Use of myocardial strain to assess global left ventricular function: a comparison with cardiac magnetic resonance and 3-dimensional echocardiography. Am Heart J. (2009) 157:102.e1–5. 10.1016/j.ahj.2008.08.032
    1. Liu J, Banchs J, Mousavi N, Plana JC, Scherrer-Crosbie M, Thavendiranathan P, et al. . Contemporary role of echocardiography for clinical decision making in patients during and after cancer therapy. JACC Cardiovasc Imaging. (2018) 11:1122–131. 10.1016/j.jcmg.2018.03.025
    1. Doherty JU, Kort S, Mehran R, Schoenhagen P, Soman P, Dehmer GJ, et al. ACC/AATS/AHA/ASE/ASNC/HRS/SCAI/SCCT/SCMR/STS 2019 Appropriate use criteria for multimodality imaging in the assessment of cardiac structure and function in nonvalvular heart disease: a report of the American college of cardiology appropriate use criteria task force, American association for thoracic surgery, American heart association, American society of echocardiography, American society of nuclear cardiology, heart rhythm society, society for cardiovascular angiography and interventions, society of cardiovascular computed tomography, society for cardiovascular magnetic resonance, and the society of thoracic surgeons. J Am Coll Cardiol. (2019) 73:488–516. 10.1016/j.jacc.2018.10.038.
    1. Negishi T, Thavendiranathan P, Negishi K, Marwick TH, SUCCOUR Investigators. Rationale and design of the strain surveillance of chemotherapy for improving cardiovascular outcomes: the SUCCOUR trial. JACC Cardiovasc Imaging. (2018) 11:1098–105.
    1. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, et al. . Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. (2010) 10:337. 10.1186/1471-2407-10-337
    1. van Dalen EC, van der Pal HJ, Kremer LC. Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy. Cochrane Database Syst Rev. (2016) 3:CD005008. 10.1002/14651858.CD005008.pub4
    1. Rafiyath SM, Rasul M, Lee B, Wei G, Lamba G, Liu D. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp Hematol Oncol. (2012) 1:10. 10.1186/2162-3619-1-10
    1. Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, et al. American heart association cardiovascular disease in, C. Special populations committee of the council on clinical, C. council on, Stroke N, C. council on quality of, and outcomes R. cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American heart association. Circulation. (2018) 137:e30–e66. 10.1161/CIR.0000000000000556
    1. Brown S. Preventive cardio-oncology: the time has come. Front. Cardiovasc. Med. (2020). 6:187. 10.3389/fcvm.2019.00187
    1. Yin BA, Brewster AM, Barac A, Thoman W, Oeffinger KC, Gilchrist SC. Cardiovascular prevention strategies in breast cancer. J Am Coll Cardiol CardioOnc. (2019) 2:322–325. 10.1016/j.jaccao.2019.09.001
    1. Barish R, Lynce F, Unger K, Barac A. Management of cardiovascular disease in women with breast cancer. Circulation. (2019) 139:1110–20. 10.1161/CIRCULATIONAHA.118.039371
    1. Nitiss KC, Nitiss JL. Twisting and ironing: doxorubicin cardiotoxicity by mitochondrial DNA damage. Clin Cancer Res. (2014) 20:4737–9. 10.1158/1078-0432.CCR-14-0821
    1. EMA European Medicines Agency. Assessment Report. Dexrazoxane-Containing Medicinal Products. EMA (2011).
    1. van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. (2011) CD003917. 10.1002/14651858.CD003917.pub4
    1. Reichardt P, Tabone MD, Mora J, Morland B, Jones RL. Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling. Future Oncol. (2018) 14:2663–676. 10.2217/fon-2018-0210
    1. Asselin BL, Devidas M, Chen L, Franco VI, Pullen J, Borowitz MJ, et al. . Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-hodgkin lymphoma: a report of the children's oncology group randomized trial pediatric oncology group 9404. J Clin Oncol. (2016) 34:854–62. 10.1200/JCO.2015.60.8851
    1. EMA European Medicines Agency. Questions and Answers on Cardioxane (Dexrazoxane: Powder for Solution for Injection: 500 mg). Outcome of a Procedure Under Article 13 of Regulation (EC) No 1234/2008. EMA (2017).
    1. Macedo AVS, Lyon AR, Nascimento BR, Putzu A, Rossi L, Costa RB, et al. Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer. J Am Coll Cardiol CardioOnc. (2019) 1:68–79. 10.1016/j.jaccao.2019.08.003
    1. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, et al. . Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. (2006) 48:2258–62. 10.1016/j.jacc.2006.07.052
    1. Kaya MG, Ozkan M, Gunebakmaz O, Akkaya H, Kaya EG, Akpek M, et al. . Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol. (2013) 167:2306–10. 10.1016/j.ijcard.2012.06.023
    1. Seicean S, Seicean A, Alan N, Plana JC, Budd GT, Marwick TH. Cardioprotective effect of beta-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail. (2013) 6:420–6. 10.1161/CIRCHEARTFAILURE.112.000055
    1. Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, et al. . Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol. (2017) 35:870–77. 10.1200/JCO.2016.68.7830
    1. Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. . Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. (2006) 114:2474–81. 10.1161/CIRCULATIONAHA.106.635144
    1. Nakamae H, Tsumura K, Terada Y, Nakane T, Nakamae M, Ohta K, et al. . Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. (2005) 104:2492–8. 10.1002/cncr.21478
    1. Cadeddu C, Piras A, Mantovani G, Deidda M, Dessi M, Madeddu C, et al. . Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J. (2010) 160:487 e1–7. 10.1016/j.ahj.2010.05.037
    1. Gulati G, Heck SL, Rosjo H, Ree AH, Hoffmann P, Hagve TA, et al. . Neurohormonal blockade and circulating cardiovascular biomarkers during anthracycline therapy in breast cancer patients: results from the PRADA (prevention of cardiac dysfunction during adjuvant breast cancer therapy) study. J Am Heart Assoc. (2017) 6:006513. 10.1161/jaha.117.006513
    1. Akpek M, Ozdogru I, Sahin O, Inanc M, Dogan A, Yazici C, et al. . Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail. (2015) 17:81–9. 10.1002/ejhf.196
    1. Bosch X, Rovira M, Sitges M, Domenech A, Ortiz-Perez JT, de Caralt TM, et al. . Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (prevention of left ventricular dysfunction with enalapril and carvedilol in patients submitted to intensive chemotherapy for the treatment of malignant hEmopathies). J Am Coll Cardiol. (2013) 61:2355–62. 10.1016/j.jacc.2013.02.072
    1. Acar Z, Kale A, Turgut M, Demircan S, Durna K, Demir S, et al. . Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol. (2011) 58:988–9. 10.1016/j.jacc.2011.05.025
    1. Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol. (2012) 60:2384–90. 10.1016/j.jacc.2012.07.067
    1. Chotenimitkhun R, D'Agostino R, Jr, Lawrence JA, Hamilton CA, Jordan JH, Vasu S, et al. . Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function. Can J Cardiol. (2015) 31:302–7. 10.1016/j.cjca.2014.11.020
    1. Vaduganathan M, Hirji SA, Qamar A, Bajaj N, Gupta A, Zaha V, et al. Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy. J Am Coll Cardiol CardioOnc. (2019) 1:54–65. 10.1016/j.jaccao.2019.08.006
    1. Elitok A, Oz F, Cizgici AY, Kilic L, Ciftci R, Sen F, et al. . Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: a prospective randomized controlled study with six-month follow-up. Cardiol J. (2014) 21:509–15. 10.5603/CJ.a2013.0150
    1. Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, Jr, das Dores Cruz F, Gonçalves Brandão SM, Rigaud VOC, et al. . Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial. J Am Coll Cardiol. (2018) 71:2281–90. 10.1016/j.jacc.2018.02.049
    1. Oliveira PJ, Bjork JA, Santos MS, Leino RL, Froberg MK, Moreno AJ, et al. . Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol Appl Pharmacol. (2004) 200:159–68. 10.1016/j.taap.2004.04.005
    1. Davis MK, Villa D, Tsang TSM, Starovoytov A, Gelmon K, Sean A, et al. Effect of eplerenone on diastolic function in women receiving anthracycline-based chemotherapy for breast cancer. J Am Coll Cardiol CardioOnc. (2019) 2:295–8. 10.1016/j.jaccao.2019.10.001
    1. Gasser CA, Audebrand A, Daglayan A, Charavin MB, Escoubet, Karpov P, et al. Prokineticin receptor-1 signaling inhibits dose- and time-dependent anthracycline-induced cardiovascular toxicity via myocardial and vascular protection. J Am Coll Cardiol CardioOnc. (2019) 1:84–102. 10.1016/j.jaccao.2019.06.003
    1. Audebrand A, Désaubry L, Nebigil CG. Targeting GPCRs against cardiotoxicity induced by anticancer treatments. Front. Cardiovasc. Med. 6:194. (2019). 10.3389/fcvm.2019.00194
    1. Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M, et al. . Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: the international cardiooncology society-one trial. Eur J Cancer. (2018) 94:126–37. 10.1016/j.ejca.2018.02.005
    1. Cardinale D, Caruso V, Cipolla CM. The breast cancer patient in the cardioncology unit. J Thorac Dis. (2018) 10:S4306–22. 10.21037/jtd.2018.10.06
    1. Ky B. JACC: CardioOncology: poised to serve a maturing, collaborative field. J Am Coll Cardiol CardioOnc. (2019) 1:131–132. 10.1016/j.jaccao.2019.06.001

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere